1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2015

Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2015" provides an overview of Wet (Neovascular / Exudative) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Wet (Neovascular / Exudative) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Wet (Neovascular / Exudative) Macular Degeneration 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Wet (Neovascular / Exudative) Macular Degeneration 26
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials 33
Prominent Drugs 34
Latest Clinical Trials News on Wet (Neovascular / Exudative) Macular Degeneration 35
Jun 15, 2015: Avalanche Biotechnologies Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration 35
May 20, 2015: Lpath Reports Results for iSONEP in Patients with Wet Age-related Macular Degeneration 36
May 14, 2015: Avalanche Biotechnologies Presents Three Posters at American Society of Gene and Cell Therapy Annual Meeting 37
May 11, 2015: Ophthotech Completes Patient Recruitment of the First Phase 3 Pivotal Trial of Fovista Anti-PDGF Therapy in Combination with Lucentis in Wet Age-Related Macular Degeneration Program 37
May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference 38
May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice 39
Apr 29, 2015: Tyrogenex Initiates the APEX study, a Phase 2 Trial of Oral Treatment with X-82 for Wet AMD 39
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
Novartis AG 41
Clinical Trial Overview of Novartis AG 41
Bayer AG 44
Clinical Trial Overview of Bayer AG 44
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Regeneron Pharmaceuticals, Inc. 48
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 48
Pfizer Inc. 50
Clinical Trial Overview of Pfizer Inc. 50
Ophthotech Corp. 52
Clinical Trial Overview of Ophthotech Corp. 52
Alcon, Inc. 53
Clinical Trial Overview of Alcon, Inc. 53
Allergan Plc 54
Clinical Trial Overview of Allergan Plc 54
Valeant Pharmaceuticals International, Inc. 55
Clinical Trial Overview of Valeant Pharmaceuticals International, Inc. 55
Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 56
Clinical Trial Overview of Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 56
Clinical Trial Overview of Top Institutes / Government 57
Medical University of Vienna 57
Clinical Trial Overview of Medical University of Vienna 57
National Eye Institute 58
Clinical Trial Overview of National Eye Institute 58
University Health Network 59
Clinical Trial Overview of University Health Network 59
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 60
Clinical Trial Overview of Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 60
Azienda Ospedaliera Universitaria Integrata Verona 61
Clinical Trial Overview of Azienda Ospedaliera Universitaria Integrata Verona 61
Het Oogziekenhuis Rotterdam 62
Clinical Trial Overview of Het Oogziekenhuis Rotterdam 62
Oregon Health and Science University 63
Clinical Trial Overview of Oregon Health and Science University 63
Oslo University Hospital 64
Clinical Trial Overview of Oslo University Hospital 64
Retina Institute of Hawaii 65
Clinical Trial Overview of Retina Institute of Hawaii 65
University of Miami 66
Clinical Trial Overview of University of Miami 66
Five Key Clinical Profiles 67
Appendix 127
Abbreviations 127
Definitions 127
Research Methodology 128
Secondary Research 128
About GlobalData 129
Contact Us 129
Disclaimer 129
Source 130

List of Tables
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2015* 8
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 14
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 16
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 19
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Suspended Clinical Trials, 2015* 26
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Withdrawn Clinical Trials, 2015* 27
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Terminated Clinical Trials, 2015* 28
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 30
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 31
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 32
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 33
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 34
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 41
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2015* 44
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 46
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2015* 48
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 50
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Ophthotech Corp., 2015* 52
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Alcon, Inc., 2015* 53
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan Plc, 2015* 54
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Valeant Pharmaceuticals International, Inc., 2015* 55
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., 2015* 56
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2015* 57
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2015* 58
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2015* 59
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, 2015* 60
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Azienda Ospedaliera Universitaria Integrata Verona, 2015* 61
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Het Oogziekenhuis Rotterdam, 2015* 62
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health and Science University, 2015* 63
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Oslo University Hospital, 2015* 64
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Retina Institute of Hawaii, 2015* 65
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2015* 66

List of Figures
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 14
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 16
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 19
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 30
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 31
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 32
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 33
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 34
GlobalData Methodology 128

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.